Safety study for aggressive NK-cell leukemia patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests a new treatment approach for people with aggressive NK-cell leukemia, focusing mainly on safety. It may be offered to patients whose disease matches the study’s specific leukemia diagnosis rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of aggressive NK-cell leukemia (including if it is new or has come back).
- Your diagnosis must match the study’s agreed medical criteria based on the 2017 WHO system.
- You are not eligible to receive standard chemotherapy for your leukemia.
- If a doctor says you can use chemotherapy as your leukemia treatment, you may not qualify.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment using natural killer (NK) cells combined with antibodies to fight a type of blood cancer called acute myeloid leukemia (AML). It is for people whose AML has come back or not improved with standard treatments.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
This trial tests a new type of immunotherapy using special immune cells (NK cells) that target the CD123 marker found on AML cells. It may help people whose AML has not responded to standard treatments and who have a healthy donor available.
This early-phase study tests a combination treatment—chemo, immunotherapy, and a donor stem cell transplant—for certain aggressive NK/T-cell lymphomas. It may help patients who have advanced-stage disease by trying to improve long-term control of the cancer.
This study tests an experimental pill (HMPL-506) for people with certain types of leukemia (AML or ALL) that have not responded to standard treatments. The pill targets specific gene changes (MLL rearrangement or NPM1 mutation) to try to kill the cancer cells.
Hear when a new Aggressive NK Cell Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.